Journal of interventional cardiology最新文献

{"title":"Drug-Coated Balloon Intervention in Large Coronary Arteries: Immediate Procedural Results and One-Year Follow-Up","authors":"Alexander Loch,&nbsp;Vineesh Chandra Segaran,&nbsp;David Kwong Yi Vern,&nbsp;Victoria Wen Yeng Teoh,&nbsp;Mahmoud Danaee","doi":"10.1155/joic/6072388","DOIUrl":"https://doi.org/10.1155/joic/6072388","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Drug-coated balloons (DCBs) are an established treatment for in-stent restenosis and small-vessel coronary disease, but evidence for large de novo coronary artery lesions remains limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We prospectively evaluated patients undergoing percutaneous coronary intervention (PCI) with DCB for de novo lesions in large coronary arteries (reference vessel diameter ≥ 2.75 mm). All lesions underwent adequate predilatation, and DCBs were used as the definitive treatment strategy. Bailout stenting was performed in cases of significant recoil or flow-limiting dissection. Outcomes included procedural success, in-hospital complications, and major adverse cardiovascular events (MACEs) at 12-month follow-up, defined as cardiac death, target vessel myocardial infarction, or clinically driven target lesion revascularization (TLR).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 539 DCB-treated lesions were evaluated, of which 451 were excluded. The final cohort comprised 88 de novo lesions in large coronary vessels from 75 patients. DCB-only treatment was performed in 65.9%; 34.1% underwent additional PCI with stenting of nonindex lesions. Post-DCB dissections occurred in 50% and were predominantly NHLBI type A. Stenting was required in three cases, including one acute vessel closure, one severe recoil with residual stenosis during the index procedure, and one early vessel closure 11 h after the index procedure requiring repeat PCI. Mean acute gain on QCA was 0.93 ± 0.45 mm. Complete 12-month follow-up was achieved in 100% of patients. MACE at 12-month follow-up occurred in 2.7% (2/75), comprising one non-ST-segment elevation myocardial infarction and one clinically driven TLR. TLR was 1.3% at 12 months. One noncardiac death occurred and was not included in the MACE endpoint. No stroke or major bleeding was observed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>DCB angioplasty in selected de novo large coronary lesions was feasible and associated with high procedural success and favorable 1-year outcomes. Larger studies with longer follow-ups are warranted to confirm these findings.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2026 1","pages":""},"PeriodicalIF":1.4,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/joic/6072388","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148994593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transapical TAVR Using a Modified J-Valve for Pure Aortic Regurgitation in Large Aortic Annuli: A Single-Center Experience","authors":"Chunshui Liang,&nbsp;Mingwen Li,&nbsp;Zezhou Feng,&nbsp;Mei Yang,&nbsp;Yingbin Xiao,&nbsp;Ruiyan Ma,&nbsp;Zhao Jian","doi":"10.1155/joic/3823493","DOIUrl":"https://doi.org/10.1155/joic/3823493","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To evaluate the safety and efficacy of transapical implantation of a modified J-Valve in patients with pure aortic regurgitation (AR) and large aortic annuli (&gt; 29 mm).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective single-center study included 10 high surgical risk patients (STS-PROM: 8.3%–13.1%) with pure AR and annular diameters &gt; 29 mm who underwent transapical implantation of a J-Valve prosthesis externally reinforced with a Dacron patch between December 2018 and September 2024. Endpoints were defined according to the Valve Academic Research Consortium-3 (VARC-3) criteria. Procedural outcomes, echocardiographic data, and 30-day complications were analyzed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>All procedures were technically successful, with no intraoperative mortality, stroke, or vascular complications. Postoperatively, one patient required permanent pacemaker implantation. Perivalvular leakage (PVL) was observed in five patients (four trace/mild, one moderate) immediately postprocedure. At a median follow-up of 6.5 months, PVL was present in three patients (two trace, one moderate). Significant reductions in left ventricular dimensions and stable hemodynamic parameters were noted. No subclinical leaflet thrombosis occurred.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Transapical implantation of a modified J-Valve with an external Dacron skirt appears technically feasible with acceptable short-term safety for highly selected high-risk patients with pure AR and large annuli (&gt; 29 mm). However, the limited sample size precludes broad applicability, and longer term follow-up is required.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2026 1","pages":""},"PeriodicalIF":1.4,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/joic/3823493","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148942811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Leaving Nothing Behind in Acute Coronary Syndrome: Can Drug-Coated Balloons Deliver?","authors":"Edin Sadic,&nbsp;Sahab Sadic","doi":"10.1155/joic/1186317","DOIUrl":"https://doi.org/10.1155/joic/1186317","url":null,"abstract":"<p>Drug-coated balloons (DCBs) have emerged as an established treatment strategy for in-stent restenosis (ISR) and selected de novo coronary lesions, particularly in small vessels. Unlike stents, DCBs deliver antiproliferative therapy without leaving a permanent intracoronary implant, thereby avoiding chronic inflammation, neoatherosclerosis, and late stent-related complications. While the efficacy and safety of DCBs in ISR are well supported, data regarding their use in the setting of acute coronary syndrome (ACS) remain limited, where plaque rupture, thrombus burden, and heightened thrombotic risk raise unique procedural concerns. This review summarizes the available evidence evaluating the safety and efficacy of DCBs in ACS, including randomized controlled trials, observational studies, and registry data published over the past decade. We review outcomes across ACS subtypes, including ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI), and discuss lesion preparation strategies, thrombus management, bifurcation disease, and differences among drug-coating technologies. Current evidence suggests that, in carefully selected patients with adequate lesion preparation and acceptable angiographic results, a DCB-based strategy may offer outcomes comparable to contemporary drug-eluting stents, while potentially reducing late device-related complications and duration of dual antiplatelet therapy. Further prospective studies are needed to define optimal patient selection and procedural techniques, particularly in lesions with high thrombus burden.</p>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2026 1","pages":""},"PeriodicalIF":1.4,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/joic/1186317","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148942785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Exploratory CT-Based Anatomical Scoring System to Evaluate Suitability for Off-Label Valve Implantation in Aortic Regurgitation","authors":"Mei Liu,&nbsp;Changdong Zhang,&nbsp;Changyu Qin,&nbsp;Guangyuan Song,&nbsp;Yang Liu,&nbsp;Lingbo Zhang,&nbsp;Huan Guo,&nbsp;Shuna Xiao,&nbsp;Xiaoke Shang","doi":"10.1155/joic/4206974","DOIUrl":"https://doi.org/10.1155/joic/4206974","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objectives&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We developed an exploratory computed tomography (CT)–based anatomical scoring system for the aortic root in pure aortic regurgitation (PAR), first performed a descriptive device-level comparison between the on-label J-Valve cohort and the combined off-label Venus A-valve cohort, and then explored CT anatomical features associated with procedural risk within the off-label Venus A-Valve cohort.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;From January 2017 to January 2020, 300 patients with severe AR treated with TAVR were enrolled in a multicenter registry (J-Valve group, &lt;i&gt;n&lt;/i&gt; = 143; Venus A-Valve subgroup I, score 4–7, &lt;i&gt;n&lt;/i&gt; = 86; Venus A-Valve subgroup II, score 0–3, &lt;i&gt;n&lt;/i&gt; = 71). Device selection was Heart-Team-driven and nonrandomized. The primary analysis was a descriptive device-level comparison between the on-label J-Valve cohort and the combined off-label Venus A-Valve cohort. Secondary analyses explored outcomes within the Venus A-Valve cohort according to the empirical CT score and examined anatomical correlates of procedural risk. No adjusted or causal comparison between devices was performed.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;In the primary descriptive device-level comparison, a 30-day device success was lower in the combined Venus A-Valve cohort than in the J-Valve cohort (95/157 [60.5%] vs 132/143 [92.3%], &lt;i&gt;p&lt;/i&gt; &lt; 0.001). In the anatomically favorable Venus A-Valve subgroup I, a 30-day device success was higher than in subgroup II but remained lower than in the J-Valve cohort (71/86 [82.6%] vs 132/143 [92.3%], &lt;i&gt;p&lt;/i&gt; = 0.031); the low-score subgroup II had markedly reduced device success (24/71 [33.8%]). A 1-year all-cause mortality was 6.4% in the combined Venus A-Valve cohort versus 5.6% in the J-Valve cohort (&lt;i&gt;p&lt;/i&gt; = 0.969). Off-label Venus A-Valve use was also associated with substantially higher rates of device malposition requiring a second valve (30.6% vs 1.4%, &lt;i&gt;p&lt;/i&gt; &lt; 0.001), new LBBB at discharge (44.6% vs 18.9%, &lt;i&gt;p&lt;/i&gt; &lt; 0.001), and permanent pacemaker implantation (12.7% vs 3.5%, &lt;i&gt;p&lt;/i&gt; = 0.007). Within the Venus cohort, low-score anatomy was associated with higher procedural hazard.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;In this registry, device-level comparisons between J-Valve and Venus A-Valve should be interpreted as descriptive only because treatment allocation was nonrandomized, anatomy-driven, and unadjusted. Off-label Venus A-Valve implantation may be feasible in selected patients with favorable CT anatomy, but clinically important sa","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2026 1","pages":""},"PeriodicalIF":1.4,"publicationDate":"2026-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/joic/4206974","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148943400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of HALP Score in Predicting the Prognosis of FFR-Negative Stable Coronary Artery Disease","authors":"Oktay Şenöz,&nbsp;Yusuf Demir,&nbsp;Ahmet Anıl Başkurt,&nbsp;Samet Sevinç","doi":"10.1155/joic/8395100","DOIUrl":"https://doi.org/10.1155/joic/8395100","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Chronic coronary syndrome (CCS) is a dynamic process, and stable coronary artery plaques can progress over time and lead to ischemia. Early detection of these patients is of great importance for closer monitoring and optimization of treatment. In this study, we investigated the usefulness of the HALP score in predicting progression to critical coronary artery disease (CAD) in patients with noncritical stenosis detected by fractional flow reserve (FFR).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 181 patients who were followed up due to CCS and whose FFR value was &gt; 0.8 and who were decided to be followed up medically were included in the study. This is a retrospective cohort study. Patients were followed up through hospital records after the FFR date. Patients were divided into two groups for analysis: those who did not progress to critical CAD (Group 1) and those who did (Group 2). The HALP score was calculated according to the formula: hemoglobin (g/L) × albumin (g/L) × lymphocytes (10⁹/L)/platelets (10⁹/L).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 181 patients included in the study, 111 (61.3%) were male. The mean age of these patients was 60.3 ± 10.6 (min: 26, max: 83) years. Of the coronary arteries undergoing FFR, 126 (69.6%) were LAD, 20 (11.1%) were CX, and 35 (19.3%) were RCA. The mean follow-up period after FFR was 19.9 ± 10.6 months. The mean HALP score was significantly lower in Group 2 (64.9 ± 34.8 vs 46.4 ± 18.9, <i>p</i> = 0.002). Cox regression analysis demonstrated low preadenosine FFR (hazard ratio [HR]: 0.897; 95% confidence interval [CI]: 0.818–0.984; <i>p</i> = 0.022), and low HALP score (HR: 0.980; 95% CI: 0.967–0.994; <i>p</i> = 0.004) as independent predictors of PCI requirement during follow-up. As a predictor of PCI requirement during follow-up, the ROC curve analysis revealed a sensitivity of 65% and specificity of 61% for HALP score &lt; 50.5 (area under the curve [AUC] 0.673, 95% CI: 0.582–0.764, <i>p</i> = 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Low HALP score may be a predictor of progression of noncritical coronary artery plaques in patients with CCS.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2026 1","pages":""},"PeriodicalIF":1.4,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/joic/8395100","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148848905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unprotected Left Main Percutaneous Coronary Intervention in Patients With Moderate-to-Severe Left Ventricular Dysfunction: 15-Year Single-Centre Experience Without Routine Mechanical Support","authors":"John Ahn,&nbsp;Tim Glenie,&nbsp;Ali Khan","doi":"10.1155/joic/6691116","DOIUrl":"https://doi.org/10.1155/joic/6691116","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Left main coronary artery disease in patients with significant left ventricular (LV) dysfunction is associated with elevated procedural risk for both surgical and percutaneous interventions. Mechanical circulatory support is increasingly used empirically for high-risk percutaneous coronary interventions (PCI), but availability remains limited in many catheterisation laboratories. We report outcomes of unprotected left main PCI (LM-PCI) in patients with moderate-to-severe LV dysfunction (LVEF ≤ 35%) performed without routine periprocedural mechanical support over 15 years at a tertiary New Zealand centre.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients undergoing unprotected LM-PCI at North Shore Hospital between December 2007 and September 2023 were retrospectively identified. Baseline demographics, procedural characteristics, and outcomes were collected. Primary outcomes included in-hospital mortality, 30-days mortality, and 1-year all-cause mortality. Secondary outcomes were major adverse cardiovascular events (MACE) within 1 year, including cardiogenic shock, myocardial infarction, stroke, target vessel revascularisation, and procedural complications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Seventy-four eligible cases were analysed for this study. Median age was 72 years. 74.3% had severely impaired LVEF of 30% or less. Indications for coronary intervention included NSTEMI (41.9%), cardiomyopathy (28.4%), STEMI (8.1%), and cardiac arrest (9.5%). In-hospital mortality was seen in 1 patient (1.4%), with no death at 30 days. One-year mortality was 8.1%. Total MACE outcomes at 1-year occurred in 3 patients (4.4%); all myocardial infarction, and 1 of these patients (1.5%), had target vessel revascularisation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In our retrospective single-centre analysis, we found low rates of mortality and MACE, in unprotected LM-PCI cases without periprocedural mechanical haemodynamic support, in patients with moderate to severely impaired LVEF. These data suggest that careful patient selection and procedural planning may allow safe LM-PCI in high-risk patients even when mechanical circulatory support is not available.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2026 1","pages":""},"PeriodicalIF":1.4,"publicationDate":"2026-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/joic/6691116","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148752645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Excimer Laser Coronary Atherectomy Versus Standard Percutaneous Coronary Intervention in Acute Coronary Syndrome: A Comparative Systematic Review and Meta-Analysis","authors":"Nour Edin Darwish,&nbsp;Ahmed Mohamed Hamdy,&nbsp;Jamal Ahmad,&nbsp;Yusof Mohamed Omar,&nbsp;Elsayed S. Moubarak,&nbsp;Ameer Shashtari,&nbsp;Alaa R. AL-Ihribat,&nbsp;Omar Hammam Salloum,&nbsp;Wasef Alhroub,&nbsp;Abdel-Hady El-Gilany","doi":"10.1155/joic/1251897","DOIUrl":"https://doi.org/10.1155/joic/1251897","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Although excimer laser coronary atherectomy (ELCA) is used to reduce thrombus burden during percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), its clinical benefit remains controversial. Previous studies have yielded inconsistent results, and current literature lacks quantitative synthesis. We aimed to evaluate the safety and efficacy of ELCA versus PCI alone in patients with ACS through a systematic review and meta-analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We searched PubMed, Web of Science, Scopus, Embase, and CENTRAL through December 2025 for randomized trials and observational studies comparing ELCA-assisted PCI versus PCI alone in patients with ACS. The primary outcome was major adverse cardiovascular events (MACE). Secondary outcomes included other clinical endpoints (e.g., mortality, revascularization), procedural complications, and angiographic metrics. Risk ratios (RR) and mean differences (MDs) were pooled using fixed-effects models, selected due to the limited number of included studies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Eleven studies were included in the qualitative review, while eight studies (one trial and seven observational studies) were included in the quantitative analysis. Regarding clinical outcomes, there were no significant differences in the primary endpoint of MACE (RR 0.90, 95% CI 0.62–1.29) or secondary endpoints such as cardiovascular death and myocardial infarction; however, ELCA significantly reduced target lesion revascularization (RR 0.06, 95% CI 0.01–0.48). Procedural complications, such as slow/no-reflow and distal embolization, were comparable between groups. Angiographically, while most metrics (e.g., final TIMI flow and myocardial blush grade) showed no difference, ELCA significantly improved complete ST-segment resolution (RR 1.37, 95% CI 1.06–1.77) and reduced percent diameter stenosis (MD −2.20, 95% CI −3.56 to −0.83).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>ELCA-assisted PCI appears safe and improves vessel patency, ST-segment resolution, and target lesion revascularization rates; however, these mechanistic benefits did not translate into reduced MACE or mortality compared with standard PCI. Given the low certainty of the existing observational data and heterogeneity in angiographic outcomes, large-scale randomized trials are required to confirm these findings and define the optimal target population.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2026 1","pages":""},"PeriodicalIF":1.4,"publicationDate":"2026-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/joic/1251897","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148615344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NAT10 Promotes ox-LDL-Induced Endothelial Ferroptosis by Stabilizing TFRC mRNA via ac4C Modification","authors":"Wenjuan Zhang,&nbsp;Lingfeng Zha,&nbsp;Jiangtao Dong","doi":"10.1155/joic/6742480","DOIUrl":"https://doi.org/10.1155/joic/6742480","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Atherosclerosis (AS) is a chronic inflammatory disease characterized by lipid deposition. Ferroptosis is a form of cell death driven by the accumulation of peroxidized lipids. N⁴-acetylcytidine (ac⁴C) is an RNA modification catalyzed by N-acetyltransferase 10 (NAT10). This study aimed to elucidate the effect and mechanism of NAT10-mediated ac⁴C modification on ferroptosis in an in vitro cellular model of AS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Human vascular endothelial cells (HVECs) were treated with oxidized low-density lipoprotein (ox-LDL) to establish a cell model. A dot blot assay was used to assess the ac⁴C level, and quantitative real-time polymerase chain reaction (qPCR) and Western blot were used to detect NAT10 expression in ox-LDL-treated HVECs. The function of NAT10 was evaluated in vitro using a cell counting kit-8, lactate dehydrogenase, Fe²⁺, malondialdehyde, reactive oxygen species, and glutathione detection kits, as well as PI staining. The underlying mechanism was investigated using ac⁴C RNA immunoprecipitation (RIP), bioinformatic analysis, a dual-luciferase reporter assay, and RNA stability assays.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The levels of ac⁴C and NAT10 were elevated in ox-LDL-stimulated HVECs. Knockdown of NAT10-inhibited ferroptosis in ox-LDL-treated HVECs. Furthermore, NAT10 knockdown reduced the ac⁴C level and mRNA stability of TFRC. Additional analysis revealed that TFRC overexpression reversed the inhibitory effect on ferroptosis in HVECs following NAT10 knockdown.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In conclusion, we demonstrated that silencing of NAT10-inhibited ferroptosis in HVECs by reducing the ac⁴C modification and mRNA stability of TFRC. These findings suggest a potential novel mechanism relevant to AS pathogenesis, although further in vivo validation is warranted.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2026 1","pages":""},"PeriodicalIF":1.4,"publicationDate":"2026-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/joic/6742480","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148467635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcatheter Tricuspid Valve Replacement in Patients After Prior Left-Sided Valve Surgery: A Multicenter Retrospective Analysis","authors":"Tianyuan Xiong,&nbsp;Yi Zhang,&nbsp;Fan Qiao,&nbsp;Yuan Feng,&nbsp;Zhengang Zhao,&nbsp;Xin Wei,&nbsp;Xi Li,&nbsp;Fei Chen,&nbsp;Xingyu Ji,&nbsp;Junbo Ge,&nbsp;Fanglin Lu,&nbsp;Mao Chen","doi":"10.1155/joic/8817783","DOIUrl":"https://doi.org/10.1155/joic/8817783","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Functional tricuspid regurgitation (TR) after previous left-sided valve surgery (LSVS) represents a significant proportion of all isolated TR cases; tricuspid valve reoperation in such patients, often in the advanced stage of disease, is historically regarded as high-risk. Percutaneous transcatheter–based therapies for TR emerge as a potential solution. We sought to verify the performance of the LuX-Valve Plus system in patients with a history of LSVS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A post hoc analysis of patients enrolled in the first-in-man and confirmatory study and an investigator-initiated trial of the LuX-Valve Plus system was conducted. Multiple endpoints, including mortality, valve performance, and functional status, were compared between patients with or without a history of LSVS. Propensity score matching (PSM) was used to minimize baseline differences between groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The study included 153 patients, with 56 patients having prior LSVS. After PSM, there were a total of 46 matched pairs. All-cause mortality at 6 months was similar between groups (2.38% vs. 0%, respectively). Less-than-moderate paravalvular leakage and central TR were consistently observed in approximately 85% and 95% of patients through 6 months. Patients after prior LSVS achieved similar functional outcome in terms of the proportion of patients in NYHA Class I–II at 6 months (81.25% vs. 95.83%, <i>p</i> = 0.221). The Kansas City Cardiomyopathy Questionnaire score improved significantly after the procedure.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In this small-scale study, transcatheter implantation of the LuX-Valve Plus for TR appeared to be safe and effective in patients with a history of LSVS, showing lower short-term mortality and a degree of TR correction comparable to surgical outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2026 1","pages":""},"PeriodicalIF":1.4,"publicationDate":"2026-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/joic/8817783","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148467190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Percutaneous Closure of Patent Foramen Ovale: Expert Opinion and Proposed Framework on Procedural Aspects and Imaging Techniques","authors":"Gilles Montalescot,&nbsp;Laura Sanchis,&nbsp;Felipe Hernandez,&nbsp;Daniela Trabattoni,&nbsp;Bert Albers,&nbsp;Peter Nordbeck,&nbsp;Mark Turner,&nbsp;Nadjib Hammoudi","doi":"10.1155/joic/6900561","DOIUrl":"https://doi.org/10.1155/joic/6900561","url":null,"abstract":"<p>Transcatheter closure of the patent foramen ovale (PFO) is an established therapy for patients who have had a cryptogenic stroke in the presence of a PFO. However, limited guidance is available to support a consistent and standardized approach regarding imaging during the intervention and during follow-up and management of patients who underwent PFO closure. The present expert opinion was developed by European clinical experts experienced in transcatheter PFO closure, based on the experts’ clinical experience and available clinical evidence. The primary aim is to propose a framework providing guidance for the use of imaging prior to and during the intervention, as well as during follow-up. Aspects addressed include exploration of the relevant anatomy and identification of anatomical risk factors, device sizing, prevention and management of residual shunting, endocarditis, and new-onset atrial fibrillation, and the use of nickel-containing devices. Additional aspects related to maintaining a high quality of care are addressed.</p>","PeriodicalId":16329,"journal":{"name":"Journal of interventional cardiology","volume":"2026 1","pages":""},"PeriodicalIF":1.4,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/joic/6900561","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148462715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}